Direct Meds Review
Best for: listed for transparent disclosure — see FDA warning and BBB complaint pattern before considering
Direct Meds is a Utah-based telehealth provider offering compounded semaglutide and tirzepatide in injection and sublingual formats. Listed here with full disclosure of a September 2025 FDA warning letter for misleading marketing, plus a documented pattern of customers reporting unexpected 3-month commitment charges — see warnings and cons before considering.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Direct Meds is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Sublingual | compounded | $249 |
| Injection | compounded | $297 |
| Sublingual | compounded | $399 |
| Injection | compounded | $399 |
✓ Pros
- •Both semaglutide and tirzepatide available in injection and sublingual formats
- •All-inclusive pricing with medication, consultations, supplies, and 1–2 day temperature-controlled shipping
- •LegitScript certification confirmed (verified December 2025)
- •Named 503A pharmacy partners: CraftedRx (Warrenton, MO) and ChemistryRx (Folcroft, PA)
✗ Cons
- •FDA warning letter September 9, 2025 for misleading marketing of compounded GLP-1s as equivalent to FDA-approved drugs — compliance status post-warning not publicly documented
- •Extensive Better Business Bureau complaint pattern (rating 1.12/5 across 226 reviews as of April 2026) documenting a hidden 3-month commitment trap: multiple users report being charged $940+ for a 3-month supply when they believed they were purchasing 1 month. Direct Meds disputes the characterization but the complaint volume is material
- •Katalys program name 'Direct Meds GLP-1 Offers Top Funnels' and $280 CPA payout indicate aggressive performance-marketing optimization, which can correlate with conversion-first UX patterns
- •Rating discrepancy: Trustpilot 4.6/5 from 7,500+ reviews vs. BBB 1.12/5 from 226 reviews — suggests either review-solicitation bias or genuine unresolved customer experience issues
- •Not available in Mississippi, Louisiana, or California
- •Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- •Incorporated May 2024 — less than 2 years of operational history
- •Auto-renewal continues until manual email cancellation; BBB complaints report retention-department friction and hold times exceeding 15 minutes
Ready to start with Direct Meds?
Starting at $249/month. See current pricing and start your free consultation.
Sources & methodology
Our Direct Meds review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Direct Meds
Alan Meds
Best for: budget-conscious shoppers
Editorial score · methodology
Amazon Pharmacy
Best for: fastest brand-name Foundayo delivery with the cheapest insured price
Editorial score · methodology
AmberHealth
Best for: budget-conscious shoppers
Editorial score · methodology
Frequently Asked Questions
Ready to start with Direct Meds?
Starting at $249/month. See current pricing and start your free consultation.